Download PDF
Hamostaseologie 2000; 20(01): 44-47
DOI: 10.1055/s-0037-1619468
Original article
Schattauer GmbH

Therapie bei erworbenen Inhibitoren gegen plasmatische Gerinnungsfaktoren

Treatment of Acquried Inhibitors against Coagulation Factors
Esther O. Meili
1   Departement Innere Medizin, Abteilung Hämatologie, Universitätsspital, Zürich
› Author Affiliations
Further Information

Publication History

Publication Date:
22 December 2017 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Spezifische, neutralisierende Inhibitoren und unspezifische Inhibitoren, die durch Komplexbildung mit einem Gerinnungsfaktor und dessen rascher Elimination ebenfalls zu Faktormangel führen, können schwere Blutungen verursachen. Diagnostisch müssen sie unterschieden werden von Antiphospholipid-Antikörpern, die nicht zu einer hämorrhagischen Diathese führen. Aufgrund der heutigen Kenntnisse und eigener Beobachtungen an solchen Patienten werden die aktuellen Behandlungsstrategien erläutert: 1. Allgemeine Maßnahmen (Absetzen von Medikamenten, welche die Gerinnung zusätzlich beeinträchtigen, Unterlassen von nicht vital notwendigen diagnostischen oder therapeutischen Eingriffen), 2. Spezifische Blutstillung mit Gerinnungspräparaten, soweit diese nötig ist; bei den häufigsten Inhibitoren gegen Faktor VIII vorzugsweise mit rekombinantem aktiviertem Faktor VII (NovoSeven®), da dieser den Inhibitor nicht stimuliert. 3. Maßnahmen zur Elimination des Inhibitors: Immunsuppressiva, eventuell kombiniert mit Apherese und Immunadsorption, in Ergänzung zur Behandlung der zugrundeliegenden Krankheit, falls eine solche möglich ist.

Summary

Specific neutralizing inhibitors and unspecific inhibitors, which eliminate coagulation factors by complex formation, lead to factor deficiencies with the risk of severe bleeding. They have to be distinguished from antiphospholipid antibodies with an in vitro inhibiting effect only. Treatment strategies are explained basing upon current knowledge and our proper observations in these patients: 1. General measures: To avoid medication which impairs blood coagulation and to avoid non-vital invasive diagnostic and therapeutic interventions. 2. Specific haemostasis with coagulation concentrates, if necessary. In case of the most frequent inhibitors against factor VIII preferably recombinant activated factor VII (Novo Seven®), since NovoSeven does not stimulate inhibitor formation. 3. Measures to eliminate the inhibitor: Immunosuppressives, with or without apheresis and immunoadsorption, if possible in addition to the treatment of the underlying disorder.

Schlüsselwörter

Blutgerinnung - Inhibitoren - Faktor-VIII-Inhibitoren - Von-Willebrand-Syndrom

Keywords

Blood coagulation - inhibitors - factor VIII inhibitors - von Willebrand's disease.
 

  • Literatur

  • 1 Bajaj SP, Rapaport SI, Fierer DS, Herbst KD, Schwartz DB. A mechanism for the hypoprothrombinemia of the acquired Hypoprothrombinemia-Lupus Anticoagulant syndrome. Blood 1983; 61: 684-92.
    PubMedGoogle Scholar
  • 2 Bayer RL, Lichtman SM, Allen SL, Budman DR, Buchbinder A, Fetten J, Kolitz J, Loscalzo J. Acquired factor VIII inhibitors – successful treatment with an oral outpatient regimen. Am J Hematol 1999; 60: 70-1.
    CrossrefPubMedGoogle Scholar
  • 3 Crenier L, Ducobu J, Des Grottes JM, Cerny J, Delaunoit C, Capel P. Low response to high-dose intravenous immunoglobulin in the treatment of acquired factor VIII inhibitor. Brit J Haematol 1996; 95: 750-3.
    CrossrefPubMedGoogle Scholar
  • 4 Federici AB, Stabile F, Castaman G, Canciani MT, Mannucci PM. Treatment of acquired von Willebrand Syndrome in patients with monoclonal gammopathy of uncertain significance: Comparison of three different therapeutic approaches. Blood 1998; 92: 2707-11.
    PubMedGoogle Scholar
  • 5 Fu YX, Kaufmann R, Rudolph AE, Collum SE, Blinder MA. Multimodality therapy of an acquired factor V inhibitor. Am J Haematol 1996; 51: 315-8.
    CrossrefPubMedGoogle Scholar
  • 6 Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to factor VIII. Thromb Haemost 1981; 45: 200-3.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Hoffmann M, Monroe DM, Roberts HR. Activated factor VII activates factors IX and Xa on the surface of activated platelets: thoughts on the mechanism of action of highdose activated factor VII. Blood Coagul Fibrinolysis 1998; 9 (Suppl. 01) S61-5.
    PubMedGoogle Scholar
  • 8 Knöbl P, Derfler K, Korninger L, Kapiotis S, Jäger U, Maier-Dobersberger T, Hörl W, Lechner K, Pabinger I. Elimination of acquired factor VIII antibodies by extracorporeal antibody-based immunoadsorption (Ig-Therasorb®). Thromb Haemost 1995; 74: 1035-8.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Lee MT, Nardi MA, Grace H, Hadzi-Nesic J, Karpatkin M. Transient hemorrhagic diathesis associated with an inhibitor of prothrombin with Lupus Anticoagulant in a 1½-year-old girl: Report of a case and review of the litera-ture. Am J Hematol 1996; 51: 307-14.
    CrossrefPubMedGoogle Scholar
  • 10 Michiels JJ, Hamulyak K, Nieuwenhuis HK, Novakova I, van Vliet HHDM. Acquired haemophilia A in women postpartum: management of bleedings episodes and natural history of the factor VIII inhibitor. Eur J Haematol 1997; 59: 105-9.
    PubMedGoogle Scholar
  • 11 Rinder MR, Richard RE, Rinder HM. Acquired vn Willebrand’s disease: A concise review. Am J Haematol 1997; 54: 139-45.
    CrossrefPubMedGoogle Scholar
  • 12 Shaffer LG, Phillips MD. Successful treatment of acquired hemophilia with oral immunosuppressive therapy. Ann Int Med 1997; 127: 206-9.
    CrossrefPubMedGoogle Scholar
  • 13 Solymoss S. Postpartum acquired factor VIII inhibitors: Results of a survey. Am J Hematol 1998; 59: 1-4.
    CrossrefPubMedGoogle Scholar